<DOC>
	<DOCNO>NCT02715726</DOCNO>
	<brief_summary>Primary Objective : To demonstrate reduction low-density lipoprotein cholesterol ( LDL-C ) alirocumab comparison ezetimibe add-on therapy stable maximally tolerated daily statin therapy high cardiovascular ( CV ) risk patient hypercholesterolemia Asia . Secondary Objectives : - To evaluate effect alirocumab lipid parameter : eg , Apolipoprotein ( Apo ) B , non-HDL-C , total cholesterol ( TC ) , lipoprotein ( Lp [ ] ) , high-density lipoprotein cholesterol ( HDL-C ) , triglyceride ( TG ) , Apo A-1 . - To evaluate safety tolerability alirocumab . - To evaluate development anti-alirocumab antibody . - To evaluate pharmacokinetics ( PK ) alirocumab .</brief_summary>
	<brief_title>Evaluation Alirocumab Versus Ezetimibe Top Statin Asia High Cardiovascular Risk Patients With Hypercholesterolemia</brief_title>
	<detailed_description>The maximum study duration 35 week per patient , include screen period 3 week , 24-week randomized treatment period , 8-week follow-up period .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Patients hypercholesterolemia establish coronary heart disease ( CHD ) CHD risk equivalent adequately control maximally tolerate daily dose statin stable dose least 4 week prior screen visit ( Week 3 ) . Exclusion criterion : Patients without establish CHD CHD risk equivalent . LDLC &lt; 70 mg/dL ( &lt; 1.81 mmol/L ) screen visit ( Week 3 ) patient history document CV disease . LDLC &lt; 100 mg/dL ( &lt; 2.59 mmol/L ) screen visit ( Week 3 ) patient without history document CV disease . Change statin dose dose regimen screen randomization . Currently take statin atorvastatin , rosuvastatin , simvastatin . Atorvastatin , rosuvastatin , simvastatin take daily take register dose . Daily dose atorvastatin 80 mg , rosuvastatin 40 mg , simvastatin 40 mg. Use cholesterol absorption inhibitor ( ie , ezetimibe ) , omega3 fatty acid ( dose â‰¥1000 mg daily ) , nicotinic acid , fibrates , bile acidbinding sequestrant , red yeast rice product past 4 week prior screen visit ( Week 3 ) . Fasting serum triglyceride &gt; 400 mg/dL ( &gt; 4.52 mmol/L ) screening period . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>